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ABO incompatibility is the most common cause of immune 
hemolytic disease of the fetus and newborn (HDFN). The 
American Academy of Pediatrics lists blood group incompatibility 
as one of the major risk factors for severe hyperbilirubinemia in 
newborns. We have estimated the risk of ABO HDFN to determine 
the need for its routine screening. Blood group data from all 
blood donors who donated in the last 10 years were collected 
and analyzed. The population prevalence of ABO blood group 
genes using the phenotype data of blood donors was estimated. 
This information was further used to calculate an incidence of 
ABO HDFN requiring intervention in the population. ABO blood 
group typing was analyzed in 425,743 blood donors. The ABO 
phenotypes of A, B, O, and AB were 22.48, 36.73, 31.59, and 9.2 
percent, respectively. The gene frequencies were 0.1733, 0.2647, 
and 0.5620 for A, B, and O, respectively. It was estimated that 
13.84 percent of group O women would give birth to a non–group 
O baby and that approximately 2.77 percent of deliveries would 
likely have ABO HDFN in the study population. In India, the 
estimated risk of ABO HDFN is 2.9 percent, with a daily 2196 
babies at risk of ABO HDFN requiring intervention. This analysis 
estimates the overall burden of ABO HDFN in the population, 
which could aid in the decision-making of policymakers, 
physicians, and community health practitioners to improve 
neonatal care. Immunohematology 2021;37:64–68. 
DOI:10.21307/immunohematology-2021-009.
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In recent years, clinical and public health efforts, such as 
red blood cell antibody screening of all pregnant women and 
administration of Rh immune globulin (RhIG) in developed 
countries, have reduced the burden of Rh hemolytic disease 
of the fetus and newborn (HDFN), ultimately resulting in 
ABO HDFN as the most common cause of immune HDFN. 
Approximately 15–25 percent of feto-maternal pairs are 
ABO incompatible (blood group O mother with non–group 
O neonate), of which 10–15 percent of neonates develop ABO 
HDFN.1,2 ABO HDFN is usually managed successfully with 
phototherapy, although it is not always a benign condition. 
Severe cases having bilirubin-induced neurologic dysfunction 
and, rarely, antenatal hydrops fetalis have been described.3 
Ethnicity plays a critical role in the prevalence and severity 
of ABO HDFN. Toy et al.4 highlighted that the prevalence of 
direct antiglobulin test positivity in a group A infant born to 
a group O mother was highest (50%) in Asians and lowest 
(31%) in Europeans.4 The current scenario of ABO HDFN 
in India is unknown; unusually severe cases requiring active 
intervention such as exchange transfusions have been reported 
from India.5,6 ABO blood group gene frequencies are useful 
to predict the risk of ABO HDFN in the population. Careful 
surveillance and early detection of infants at risk of bilirubin-
related brain injury begins with recognition of an infant’s risk 
for severe hyperbilirubinemia. It requires a systemic approach 
and awareness regarding significant risk factors for severe 
hyperbilirubinemia. This study was therefore planned to 
estimate the risk of ABO HDFN in our North Indian population 
and to assess the need for routine ABO HDFN screening.
Material and Methods
Blood group data from all blood donors who donated 
blood at a tertiary care hospital in Lucknow in the last 10 years 
(2010–2019) were collected from the hospital information 
system and analyzed. The prevalence of ABO blood group 
genes in our population using phenotype data of blood 
donors was estimated. It is assumed that gender does not 
influence ABO gene inheritance and blood group distribution; 
therefore, calculated gene frequencies can be applied to the 
female population. The data were further used to estimate the 
probability of feto-maternal ABO incompatibility and ABO 
HDFN requiring intervention.
Statistical Analysis
The frequency and percentage of each blood group (A, B, 
AB, and O) were calculated using descriptive statistics. Blood 
group allelic frequencies were calculated with the assumption 
of the Hardy-Weinberg equilibrium with Ceppellini 
oRiginal RepoRt
Statistical model for prediction of ABO 
hemolytic disease of the fetus and newborn 
in India
D.S. Patale, T.L. Lokhande, and R.K. Chaudhary
IMMUNOHEMATOLOGY, Volume 37, Number 2, 2021 65
correction.7 This iterative method yields maximum likeli-
hood estimates. It was assumed that:
• ABO blood group system is determined by three alleles 
of a single gene: A, B, and O.
• A and B are co-dominant, and they are dominant over 
O.
• In the population, genes follow the Hardy-Weinberg 
principle.
• A random sample of blood donors from the population 
was studied.
• Static allele frequencies across generations assume that 
there is no mutation and migration, population size is 
infinite, and there is no selective pressure for or against 
any genotypes.
The probability of a group O woman giving birth to a child 
with a non–group O phenotype was calculated. Maternal 
immunoglobulin (Ig)G anti-A and/or anti-B titer ≥512 
predicts the risk of ABO HDFN and the need for invasive 
treatment.8 Almost 20 percent of group O donors have 
IgG anti-A and/or anti-B titer ≥512.9 Accordingly, we have 
estimated the risk of ABO HDFN in the population.
Results
ABO blood group data of 425,743 blood donors were 
analyzed, in which 17,881 (4.2%) were female and 407,862 
(95.8%) were male. The details are summarized in Table 1. 
The study revealed that blood group B was the most prevalent 
(36.73%), closely followed by O at 31.59 percent, then A at 
22.48, percent, and AB as the least frequent group, at 9.2 
percent. The observed and expected phenotype frequencies 
are shown in Table 2. The χ2 test between the observed and 
expected phenotype frequencies in case of ABO group was not 
statistically significant (p > 0.0001).
CalCulation for gene frequenCy: 
A, B, and O were represented by letters p, q, and r.
CalCulation of O allele frequenCy (r):
The frequency of allele O is equal to the frequency of the 
recessive genotype (r2).
r2 = frequency of O phenotype ([number of group O 




CalCulation of A allele frequenCy (p):
p = frequency of the group A phenotype + frequency of the 
group O phenotype.
The frequency of A + O = p2 + 2pr + r2 = (p + r)2
p + r = √ (A + O)
p = √(A + O) – (r) 
p = √(0.2248 + 0.3159) – 0.5620
p = 0.1733
CalCulation of B allele frequenCy (q):
Because p + q + r = 1
q = 1 – (p + r)
q = 1 – (0.1733 + 0.5620)
q = 0.2647
Thus, the calculated gene frequencies were 0.1733, 0.2647, and 
0.5620 for the A, B, and O genes, respectively.
the CalCulation for the probability of non–group o Child to 
group o mother:
The probability of a non–group O child to group O mother 
will be the probability of a group OO genotype woman mating 
with a genotype AA, BB, AO, BO, or AB man, resulting in an 
offspring with the non–group O gene. Using gene frequencies 
calculated above, the probability that an OO genotype woman 
mating with an AA genotype man is the product of frequency 
of AA genotype and frequency of OO genotype:
AA = r2 × p2 = 0.00948
HDFN prediction model
Table 1. Distribution of blood groups in the study population
Blood group A B O AB
Rh(D) type Pos Neg Pos Neg Pos Neg Pos Neg Total
















Total number (%) 95,690 (22.48) 156,395 (36.73) 134,485 (31.59) 39,173 (9.20) 425,743 (100)
Pos = positive; Neg = negative.
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Similarly,
BB = r2 × q2 = 0.02214
The probability of an OO genotype woman mating with an AO 
genotype man is:
AO = r2 × 2pr
The probability of inheriting the A gene from the father is 50 
percent. Therefore, the probability of an AO man and an OO 
woman having an AO child is:




The probability of an OO genotype woman mating with an AB 
genotype man and having a child with either the A or B gene is:
AB = r2 × 2pr
AB = 0.02897
The sum of all probabilities is 0.13837.
Therefore, 13.84 percent of deliveries will result in a 
non–group O child to group O mother. Because 20 percent of 
group O mothers will have IgG anti-A and/or anti-B titer ≥512, 
ultimately 2.77 percent of deliveries in our study population 
are at risk of ABO HDFN, requiring intervention.
Discussion
In India, diversity has been observed in the geographical 
distribution of blood groups. In the present study, group B was 
the most prevalent blood group, followed by group O, in a north 
Indian population; this observation is similar to that found in 
the study by Arora et al.,10 although a multicentric study shows 
group O as the most common blood group, followed by group 
B, in India.10,11
Using ABO gene frequency, we calculated the probabilities 
of ABO incompatibility as 13.8 percent. Bhat and Kumar12 
found 17.3 percent ABO incompatibility, similar to our 
estimate. Akanmu et al.13 did a similar study in Nigeria in 
which they estimated that 14.3 percent of deliveries would 
result in feto-maternal ABO incompatibility, again similar 
to our findings. They estimated that 4.3 percent of deliveries 
are likely to suffer ABO HDFN, which is quite high compared 
with our estimation. This finding is consistent with previous 
reports stating that the incidence of ABO HDFN is higher in 
individuals of African descent. This difference can be due to 
the very high cutoff value (≥512) for antibody titer used in the 
present study.14,15
The burden of neonatal jaundice is highest in South Asia, 
where it is the seventh leading cause of neonatal mortality.16 
Various studies from India reported neonatal jaundice as the 
most common cause of neonatal morbidity, varying from 7 to 
16.7 percent.17,18 Statistical estimates allow us to project the 
overall burden of ABO HDFN in the population. Therefore, 
we extended this observation to national data and found that 
2.9 percent of neonates are at risk of ABO HDFN in India 
(Table 3). The birth rate in India is 20 per 1000 population, 
and currently the total population is 1,381,625,777.19,20 Thus, 
approximately 2196 babies are born per day who are at risk 
of ABO HDFN, requiring intervention. Barring the limitations 
associated with statistical modeling of disease burden, our 
data suggest that neonatal jaundice due to ABO HDFN is an 
important cause of neonatal morbidity.
Phototherapy and exchange transfusions are the 
mainstay treatments for severe hyperbilirubinemia, but 
these therapies require adequate infrastructure. The need for 
exchange transfusion has been reduced with the introduction 




frequency Genotype Expected frequency
A 0.2248 AA p2 0.0300 0.2247
AO 2pr 0.1947
B 0.3673 BB q2 0.0701 0.3677
BO 2qr 0.2976
O 0.3159 OO r2 0.3159 0.3159
AB 0.0920 AB 2pq 0.0917 0.0917
Total 1 1 1
p = A allele frequency; r = O allele frequency; q = B allele frequency.
Table 3. Comparison between Indian population and study 
population





Non–group O child to group O 
mother 
0.13835 0.1450
ABO HDFN requiring intervention 2.77% 2.90%
HDFN = hemolytic disease of the fetus and newborn.
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of phototherapy and intravenous immunoglobulin (IVIG) 
therapy. However, availability and cost of IVIG therapy 
are major limitations for its routine use in resource-poor 
nations. Immediate exchange transfusion is required when 
phototherapy fails to curtail the rate of bilirubin rise and 
the total serum bilirubin. Provision of exchange transfusion 
requires centers with fully equipped blood banks with 
component separation, such as a sterilized connecting device, 
leukocyte filtration, gamma irradiation, a dielectric tube sealer, 
laminar air-flow, and trained personnel. In a developing and 
resource-constrained nation such as India, infrastructure with 
facilities for special care, including monitoring and resuscita- 
tion capabilities, is most likely available at tertiary care 
hospitals. Findings of this study should help administrators 
plan for the provision of exchange transfusion when consider-
ing improvements in the Indian medical care infrastructure.
As per routine antenatal care, the blood group and Rh(D) 
type of the mother (ABO and Rh) is determined by a blood test. 
In resource-constrained areas, group O mothers should be 
tested for ABO antibody titers, and ABO-incompatible babies 
of high-risk group O mothers should be kept under vigilance. 
At present, D incompatibility is the only cause of HDFN for 
which screening is routinely done.21 Routine screening for 
ABO HDFN may be considered as an additional step in risk 
assessment of HDFN. Timely diagnosis with the appropriate 
intervention will result in a better outcome in babies at risk.
A limitation of the study is that the numbers used to 
calculate the risk of severe ABO HDFN are from a donor base 
that is likely all male, although gender does not influence ABO 
blood group distribution.
Conclusions
The estimated risk of ABO HDFN is 2.77 percent of all 
deliveries in our study population. In India, the calculated risk 
is 2.9 percent, with a daily number of 2196 babies at risk of 
ABO HDFN. A policy for routine screening of these neonates 
is needed.
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